FREITAS, L. M.; BARBOSA, M. F.; http://lattes.cnpq.br/4922004041787709; http://lattes.cnpq.br/2179218507454650; FREITAS, Larissa Mesquita.; BARBOSA, Mayara Ferro.
Resumo:
Diabetes mellitus and hypertension are chronic non-communicable diseases and are associated with morbidity and mortality, accounting for cardiovascular, brain, coronary, renal and peripheral vascular complications. The treatment is based on pharmacological and non-pharmacological measures. Among the various classes of drugs used emerged SGLT2 inhibitors for treating medical conditions of the two alone or in combination. This class has been released only for the anti-diabetic treatment. However, recent studies have pointed to its antihypertensive effect. This integrative systematic study aimed to identify the effectiveness, risks and benefits of SGLT-2 inhibitors in the treatment of type 2 diabetes mellitus associated with hypertension. For this, we performed an integrative review in the databases LILACS and MEDLINE the last decade. The use of these drugs proved safe and effective antihypertensive treatment with 4-10mmHg drops in systolic blood pressure, proving to be therapeutic options in the treatment of diabetes associated with hypertension.